Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 86 for your search:
Drug:
epirubicin hydrochloride
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
Phase:
Phase IV
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
LITE Randomized Pilot Study
, NCT00531973
2.
Yunzhi as Dietary Supplement in Breast Cancer
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
YUNZHI-BC
, NCT00647075
3.
Phase IV Study of the Correlation of Proteomic Signature With Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
COL-SPAM-0610
, SPAM-0610, COL-IDRCB-2006-A00295-46, INCA-RECF0391, NCT00959673
4.
Traditional (Traditional Chemoembolization) TACE vs Microsphere TACE
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
RAD01
, EudraCT 2006-003034-15, NCT00936689
5.
Phase II/III Randomized Study of Neoadjuvant and Adjuvant Chemotherapy Comprising Epirubicin Hydrochloride, Cisplatin, and Capecitabine With or Without Bevacizumab in Patients With Previously Untreated, Resectable Gastric or Gastroesophageal Junction Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MRC-ST03
, EU-20710, ISRCTN46020948, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203
6.
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
GEICAM/2006-14
, Nº EudraCT 2007-007031-13, NCT00841828
7.
Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Approved-not yet active
Age:
20 to 79
Sponsor:
Other
Protocol IDs:
ACE500
, NCT00843934
8.
Phase II/III Randomized Study of Adjuvant Therapy Comprising Gemcitabine Hydrochloride With Versus Without Cisplatin, Epirubicin Hydrochloride, and Fluorouracil Followed by Chemoradiotherapy With Fluorouracil or Capecitabine in Patients With Stage IB, II, or III Adenocarcinoma of the Pancreas
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
SRSI-PACT-7
, PACT-7, EU-20932, NCT00960284
9.
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
R-09-025
, NCT00907543
10.
Phase III Randomized Study of Adjuvant Induction Chemotherapy With or Without Cyclophosphamide and Methotrexate as Maintenance Chemotherapy in Patients With Stage I, II, or III Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
IBCSG-22-00
, EU-20119, NCT00022516, EUDRACT-2005-005666-36
11.
Phase III Randomized Study of Neoadjuvant Cisplatin and Fluorouracil Versus Cisplatin, Epirubicin, and Fluorouracil in Patients With Resectable Adenocarcinoma of the Esophagus
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MRC-OE05
, EU-20204, NCT00041262
12.
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID99-146
, NCT00038402
13.
A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
Other
Protocol IDs:
T1303
, NCT00201396
14.
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-Positive Primary Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 64
Sponsor:
Other
Protocol IDs:
GBG 33
, GAIN, NCT00196872
15.
Phase III Randomized Study of Neoadjuvant Epirubicin Hydrochloride, Cyclophosphamide, and Docetaxel With Versus Without Capecitabine and/or Trastuzumab (Herceptin®) Followed by Surgery in Women With Stage I-III Primary Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GBG-GEPARQUATTRO
, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002
16.
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
19 to 80
Sponsor:
Other
Protocol IDs:
ABCSG-24
, Ro 09-1978, NCT00309556
17.
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR005143
, NCT00338286
18.
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CRITICS
, NCT00407186
19.
Phase III Randomized Study of 70-Gene Signature Versus Clinical Assessment in Selecting Women With Node-Negative Breast Cancer for Adjuvant Chemotherapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-10041
, EUDRACT-2005-002625-31, BIG-3-04, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589
20.
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
CT/01.04
, NCT00424606
21.
Phase III Randomized Study of Neoadjuvant Combination Chemotherapy Comprising Fluoroucacil, Epirubicin Hydrochloride, and Cyclophosphamide Followed by Paclitaxel and Trastuzumab (Herceptin®) Versus Neoadjuvant Paclitaxel and Trastuzumab Followed by Combination Chemotherapy Comprising Fluoroucacil, Epirubicin Hydrochloride, Cyclophosphamide and Trastuzumab in Women With Palpable and Operable Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1041
, Z1041, NCT00513292
22.
Phase III Randomized Pilot Study of Adjuvant Chemotherapy Comprising Doxorubicin Hydrochloride or Epirubicin Hydrochloride and Cyclophosphamide in Older Women With Invasive Breast Carcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
70 and over
Sponsor:
Other
Protocol IDs:
UKM-CCH-ACTION
, ICR-CTSU/2006/10004-ACTION, EU-20751, EUDRACT-2005-005721, ISRCTN41708421, BIG-205, BIG 2-05, NCT00516425
23.
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
DSMM V
, NCT00546988
24.
A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Phase:
Phase III
Type:
Genetics, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GBG 44
, EudraCT No.: 2006-005834-19, NCT00567554
25.
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
QL05-37
, NCT00572572
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
